Soft Tissue Sarcoma
Methodology & AI Transparency ⓘ
Soft Tissue Sarcoma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Your soft tissues connect, support, or surround other tissues.
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C49.9 for Soft Tissue Sarcoma clinical workups.
- 3 Typical cash cost range: Primary evaluation for Soft Tissue Sarcoma incorporates immunohistochemistry [Soft Tissue Sarcoma C49.9] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Soft Tissue Sarcoma monitoring tracks Pathology / Molecular in Soft Tissue Sarcoma (C49.9: Genomic Staging) toward Guideline-concordant surveillance (C49.9).
Ask our AI Specialists anything about Soft Tissue Sarcoma
What Is Soft Tissue Sarcoma?
Your soft tissues connect, support, or surround other tissues. Examples include your muscles, tendons, fat, and blood vessels. Soft tissue sarcoma is a cancer of these soft tissues. There are many kinds, based on the type of tissue they started in. They may cause a lump or swelling in the soft tissue. Sometimes they spread and can press on nerves and organs, causing problems such as pain or trouble breathing. No one knows exactly what causes these cancers. They are not common, but you have a higher risk if you have been exposed to certain chemicals, have had radiation therapy, or have certain genetic diseases. Doctors diagnose soft tissue sarcomas with a biopsy.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Soft Tissue Sarcoma (C49.9) center on immune-checkpoint evasion [Soft Tissue Sarcoma C49.9]. Cross-referenced with NIH MeSH (Sarcoma), targeted cancer & oncology interventions aim to normalize Pathology / Molecular in Soft Tissue Sarcoma (C49.9: Genomic Staging).
Common Symptoms & Clinical Signs
- • Presentation of Soft Tissue Sarcoma (C49.9): unintended weight loss [Soft Tissue Sarcoma C49.9]
- • Secondary Soft Tissue Sarcoma clinical sign: unexplained bleeding, chronic in Soft Tissue Sarcoma (C49.9: hoarseness/cough, or progressive)
- • Symptom flares in Soft Tissue Sarcoma correlating with Pathology / Molecular in Soft Tissue Sarcoma (C49.9: Genomic Staging) deviation outside Guideline-concordant surveillance (C49.9)
- • Functional cancer & oncology impact requiring immunohistochemistry [Soft Tissue Sarcoma C49.9] evaluation (C49.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Soft Tissue Sarcoma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C49.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Soft Tissue Sarcoma (C49.9: Genomic Staging) | Guideline-concordant surveillance (C49.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Soft Tissue Sarcoma (C49.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C49.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Soft Tissue Sarcoma (C49.9: Organ Function Panel) | Preserved renal/hepatic clearance (C49.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Soft Tissue Sarcoma
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Lidocaine 4% Phenylephrine HCl 0.25% Hemorrhoid Master Nicovito Hemorrhoid Master, Alveora Hemorrhoid Master • RxCUI 2529640 | Amide Local Anesthetic | 90% | $0.0989 | $ 12.50 /mo |
| Strensiq (Asfotase Alfa) Strensiq • RxCUI 1720268 | Tissue-nonspecific Alkaline Phosphatase | 84% | $0.3100 | $ 30.82 /mo |
| Debbies Down and Dirty Deep Tissue Joint and Muscle (Menthol) Debbies Down and Dirty Deep Tissue Joint and Muscle • RxCUI 253020 | Calculi Dissolution Agent | 89% | $0.8804 | $ 71.89 /mo |
| Hemorrhoid and Fissure Cream Hemorrhoid and Fissure Cream Generic • RxCUI 2734148 | Non-Standardized Chemical Allergen | 90% | $0.2700 | $ 19.44 /mo |
| Concizumab Alhemo • RxCUI RXN-01692081-2327 | Tissue Factor Pathway Inhibitor Antagonist | 85% | $2.1500 | $ 95.58 /mo |
| Acellular Tissue Engineered Vessel Symvess • RxCUI 2700346 | FDA Prescription Therapeutic Agent | 76% | $3.4800 | $ 149.44 /mo |
| Fem Glandular and Tissue Aid Fem Repair Non-Preg • RxCUI RXN-64616090-2967 | Copper Absorption Inhibitor | 89% | $2.2900 | $ 101.25 /mo |
| Rethymic (Allogenic Thymocyte-Depleted Thymus Tissue-Agdc) Rethymic • RxCUI RXN-B72359001 | FDA Prescription Therapeutic Agent | 94% | $2.9100 | $ 218.02 /mo |
| Tenecteplase Tnkase • RxCUI 284422 | FDA Prescription Therapeutic Agent | 92% | $2.0600 | $ 91.93 /mo |
| Silver Nitrate Applicators Silver Nitrate Applicators Generic • RxCUI 1117536 | FDA Prescription Therapeutic Agent | 80% | $0.1197 | $ 13.35 /mo |
| Alhemo (Concizumab) Alhemo • RxCUI RXN-B01692081 | Tissue Factor Pathway Inhibitor Antagonist | 77% | $1.8700 | $ 143.14 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Soft Tissue Sarcoma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral: What a 1,835-Participant Study Found All doses of TX-001HR provided endometrial protection and were associated with an improved bleeding profile over time; older age, further last menstrual period, or lower baseline E2 may predict amenorrhea with TX-001HR. Menopause (New York, N.Y.) • 2020-04-15 • Phase III Randomized Trial | N = 1,835 | 96/100 | PMID 31913228 ↗ |
| New Insights on Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage: What a 1,017-Participant Study Found In this first ctDNA assessment of a large series of patients with stage III colon cancer enrolled in phase III trial, post-surgery ctDNA was found in 13.8% of them and was confirmed as an independent prognostic marker. Clinical cancer research : an official journal of the American Association for Cancer Research • 2021-10-15 • Phase III Randomized Trial | N = 1,017 | 90/100 | PMID 34083233 ↗ |
| Can This Approach Help? Inside the Latest Research on 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) Women treated with E2/P4 had a greater response to treatment with more VMS-free days than with placebo. Menopause (New York, N.Y.) • 2020-12-15 • Randomized Controlled Trial | N = 141 | 88/100 | PMID 32740481 ↗ |
| Can This Approach Help? Inside the Latest Research on Safety and real-world benefits of a single dose of oral azithromycin given in There was a modest relative reduction in infant SSTIs but this was small in absolute terms with no statistically discernible difference. BMC medicine • 2025-04-28 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40289086 ↗ |
| Can This Approach Help? Inside the Latest Research on Assessing the ability of boys with Duchenne muscular dystrophy age 4-7 years to Most (97%; 175/181) patients screened were able to swallow capsules. Journal of clinical pharmacy and therapeutics • 2022-01-15 • Phase III Randomized Trial | N = 131 | 88/100 | PMID 34263472 ↗ |
Soft Tissue Sarcoma Patient Community & “People Like Me” Threads
Filter Soft Tissue Sarcoma community threads and patient logs by age, biological sex, dosage, and treatment duration.